Global Intraocular Lens Market Size, Share & Industry Trends Analysis Report By End-use, By Product (Multifocal, Monofocal, Toric, and Accommodative), By Regional Outlook and Forecast, 2021 - 2027

Global Intraocular Lens Market Size, Share & Industry Trends Analysis Report By End-use, By Product (Multifocal, Monofocal, Toric, and Accommodative), By Regional Outlook and Forecast, 2021 - 2027

The Global Intraocular Lens Market size is expected to reach $5.1 billion by 2027, rising at a market growth of 5.0% CAGR during the forecast period.

An intraocular lens is an artificial lens that is implanted in the eye during cataract surgery to replace the natural lens. The worldwide intraocular lens market is predicted to develop as the senior population becomes more sensitive to ocular disorders, cataract prevalence rises, and government measures to eradicate avoidable blindness increase. Furthermore, the market's growth is aided by an increase in the usage of premium lenses, which provide benefits such as improved visual performance and decreased astigmatism. However, the market is projected to be hampered by an unfavorable reimbursement environment for premium lenses, as well as postoperative problems such as refractive errors.

The front face of traditional intraocular lenses is consistently curved from the lens's centre to its perimeter, resulting in a spherical optical design. However a spherical IOL is simple to make, it does not replicate the form of the natural lens within the eye, which has a varying curvature from centre to periphery. In other words, the normal lens of the eye is aspheric ("not spherical"). Higher-order aberrations (HOAs) are tiny optical flaws caused by a spherical intraocular lens that can impact vision quality, especially in low-light situations like driving at night.

The growing number of geriatric and diabetic people, who are more likely to acquire cataracts and other vision problems, is predicted to boost market development. Furthermore, growing awareness of visual impairments, increased healthcare expenditure, and government assistance to develop healthcare infrastructure are among the major drivers driving market expansion.

Impact of COVID 19

Routine healthcare visits were cancelled as a result of the COVID-19 outbreak in December 2019, in order to prevent people from catching the virus. In the first half of 2020, this had a negative influence on the market. There was a considerable decline in procedure volumes since many patients were older and at a higher risk of developing COVID-19 symptoms, resulting in revenue loss and the temporary or permanent shutdown of single ophthalmic practise units.

Nevertheless, as a consequence of the reopening of several medical institutions and practises in the later part of 2020, patients volumes increased. Furthermore, the use of modified face-to-face visits and telecommunication permitted for the continuation of a modest number of surgeries throughout the pandemic's height. However, certain operations, such as cataract surgery, are still experiencing a backlog.

Market Growth Factors

Eye disorders and vision impairment are becoming more common

Low vision and blindness are major global public health issues that are becoming more common as a result of demographic shifts and ageing populations. The number and proportion of persons above the age of 65 is increasing. Vision loss is common among the elderly, and it has a negative impact on their quality of life. Losing one's ability to see is a life-changing event for those who are impacted and their family. But that's not all: being the most severe ocular problem consequence, blindness indicates a lot about the population's overall disease burden. As a result, the occurrence of blindness and visual impairment is a good indication of overall health.

The demand for refractive surgery evaluation Is growing

The segment's dominance in refractive surgery assessment can be attributed to a rising need to meet the growing number of patients of uncorrected refraction and corneal opacity across the world. Furthermore, cataract surgery is becoming more widely accepted as the best option for recovering eyesight in persons with cataracts. According to World Health Organization (WHO) predictions for 2019, about 123.7 million individuals have visual loss due to uncorrected refractive error, 65.2 million people have cataracts, 6.9 million people have glaucoma, and 4.2 million people have corneal opacity. The Cataract Surgery assessment sector, on the other hand, is estimated to develop the quickest over the forecast period due to growing usage of corneal topographers in the sector due to technological improvements that boost market demand.

Market Restraining Factors

Trained ophthalmology surgeons are in short availability

A World Health Organization examination of 1.5 million individuals that year revealed that around 9 million people were blind, with cataract causing 4 million cases of blindness. In comparison to other medical fields, ophthalmology relies more on specialized equipment and knowledge, and a dearth of both has resulted in a substantial unmet need for eye care centers in the 1.2 billion-strong country. Governments are undertaking measures to improve eye health, but insufficient eye care services and limited funding have hampered plans.

End-Use Outlook

Based on End-use, the market is segmented into Hospitals, Ophthalmic Clinics, Eye Research Institutes, and Ambulatory Surgery Centers. Because the majority of cataract and vision correction procedures are conducted in hospitals, the hospitals sector led the market in 2021. Individual ophthalmic clinics are increasing in number in developing countries. There are no hospitals associated with these clinics. The rivalry among service providers is projected to heat up as the number of eye care practitioners and clinics grows. The provision of treatments at low pricing is likely to boost the number of people choosing these clinics for treatment, fuelling segment expansion.

Product Outlook

Based on Product, the market is segmented into Multifocal, Monofocal, Toric, and Accommodative. The toric intraocular lens sector, which is advantageous primarily for patients with moderate to high astigmatism, was the second-largest segment in 2021 and is predicted to rise at a profitable pace throughout the projection period. Astigmatism causes myopia, hypermetropia, or both in patients. Toric intraocular lenses are made particularly for such people. Furthermore, toric IOLs are meant to minimize the necessity for incision implants, which were previously necessary during astigmatism surgical operations, enhancing their popularity among people.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia Pacific is predicted to expand at the quickest rate. The existence of a high elderly and diabetic population, both of whom are susceptible to cataracts and other ocular illnesses, is driving the market in this area. Furthermore, the market is growing due to increased knowledge of improved treatment alternatives and an inflow of people from wealthy nations seeking cheap healthcare.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include EyeKon Medical, Inc., Lenstec, Inc., HumanOptics AG, STAAR Surgical Company, Rayner Intraocular Lenses Limited, Bausch Health Companies, Inc., Carl Zeiss AG, Johnson & Johnson (Johnson & Johnson Vision Care, Inc.), Hoya Corporation, and Alcon, Inc.

Strategies Deployed in Intraocular Lens Market

Nov-2020: Alcon launched AcrySof IQ Vivity, a first-of-its-kind, surgical lens. This lens is designed for cataract patients to treat presbyopia, a common, age-related vision condition caused by the gradual loss of the eye's ability to focus on close objects. In addition, this latest innovation in Alcon's portfolio of presbyopia-correcting intraocular lenses, AcrySof IQ Vivity utilizes a non-diffractive design called X-WAVE technology that sets apart it from other intraocular lenses currently on the market.

ct-2020: Bausch + Lomb launched SimplifEYE intraocular lens (IOL) delivery system in the US. SimplifEYE IOL provides a delivery system for the enVista MX60PL and the enVista toric MX60PT monofocal preloaded intraocular lenses (IOLs). It offers easy and consistent implantation of enVista lenses into the capsular bag in three steps through an incision as small as 2.2mm.

Sep-2020: Rayner introduced RayOne EMV, a new fully loaded non-diffractive IOL. This product is designed to enhance patient results achieved with monovision. RayOne EMV expands a patient’s range of vision with a patented non-diffractive aspheric optic profile.

May-2020: Bausch + Lomb released its first presbyopia-correcting intraocular lens (IOL), LuxSmart, and its monofocal version, LuxGood. In addition, both of these lenses feature preloaded delivery systems and Pure Refractive Optics (PRO) Technology.

Dec-2019: Johnson & Johnson received the FDA approval for the Tecnis Toric II one-piece intraocular lens (IOL). This product provides more surface texture and friction on IOL haptics, which holds an IOL in position within the eye. In addition, this lens would deliver visual improvement for different visual conditions and lifestyles.

Dec-2019: Bausch + Lomb introduced enVista toric MX60ET hydrophobic acrylic intraocular lens (IOL). The MX60ET with StableFlex technology includes advanced material properties that offer enhanced optic recovery following delivery during cataract surgery.

Mar-2019: Alcon took over PowerVision, a US-based medical device development company. This acquisition aimed to bring the innovative, accommodating lens to cataract patients across the globe.

Scope of the Study

Market Segments covered in the Report:

By End-Use

• Hospitals
• Ophthalmic Clinics
• Eye Research Institutes
• Ambulatory Surgery Centers

By Product

• Multifocal
• Monofocal
• Toric
• Accommodative

By Geography

• North America

US

Canada

Mexico

Rest of North America

• Europe

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

• Asia Pacific

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

• LAMEA

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

Companies Profiled

• EyeKon Medical, Inc.
• Lenstec, Inc.
• HumanOptics AG
• STAAR Surgical Company
• Rayner Intraocular Lenses Limited
• Bausch Health Companies, Inc.
• Carl Zeiss AG
• Johnson & Johnson (Johnson & Johnson Vision Care, Inc.)
• Hoya Corporation
• Alcon, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free